8-K: MaxCyte Reports Slight Core Revenue Growth in Q1 2025, Reaffirms Full-Year Guidance

MaxCyte announced its Q1 2025 financial results, showing a slight increase in core revenue and reiterating its full-year 2025 guidance.

Summary

• MaxCyte reported a total revenue of $10.4 million for the first quarter of 2025, which is an 8% decrease compared to $11.3 million in the first quarter of 2024.
• Core business revenue increased by 1% to $8.2 million in Q1 2025.
• SPL Program-related revenue decreased to $2.1 million from $3.2 million in the same quarter last year.
• The company added one new SPL client, TG Therapeutics, bringing the total to 29 active SPLs.
• MaxCyte's gross profit for Q1 2025 was $8.9 million, with a gross margin of 86%.
• The company's net loss for the quarter was $10.3 million, compared to a net loss of $9.5 million in Q1 2024.
• MaxCyte is reiterating its 2025 core revenue growth guidance of 8% to 15%, including revenue from SeQure Dx.
• SPL Program-related revenue is expected to be approximately $5 million for the year.
• The company anticipates ending 2025 with approximately $160 million in cash, cash equivalents, and investments.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While total revenue decreased, core revenue showed slight growth, and the company reiterated its full-year guidance. The management expresses confidence in future growth, but there are also acknowledged challenges.

Positives

• Core business revenue saw a slight increase of 1% in the first quarter of 2025, reaching $8.2 million.
• MaxCyte successfully added a new SPL client, TG Therapeutics, in February, expanding its active SPL portfolio to 29.
• The company maintains a strong financial position with $174.7 million in total cash, cash equivalents, and investments as of March 31, 2025.
• MaxCyte reiterated its 2025 revenue guidance for core business revenue and SPL Program-related revenue.
• The integration of SeQure Dx is progressing smoothly, presenting a substantial long-term opportunity for safety assessment services.

Negatives

• Total revenue decreased by 8% to $10.4 million in the first quarter of 2025, compared to $11.3 million in the first quarter of 2024.
• SPL Program-related revenue decreased from $3.2 million in Q1 2024 to $2.1 million in Q1 2025, a 32% decrease.
• The company experienced a net loss of $10.3 million for the first quarter of 2025, compared to a net loss of $9.5 million for the same period in 2024.

Risks

• The company faces a dynamic macroeconomic environment that could impact its growth.
• The decrease in SPL Program-related revenue could indicate challenges in securing or maintaining these partnerships.
• The company's forward-looking statements are subject to risks and uncertainties, including those related to market conditions and competition.

Future Outlook

MaxCyte reiterates its 2025 revenue guidance, expecting core revenue to grow 8% to 15% compared to 2024, including revenue from SeQure Dx, and SPL Program-related revenue to be approximately $5 million. The company expects to end 2025 with approximately $160 million in total cash, cash equivalents, and investments.

Management Comments

• MaxCyte has had a good start to 2025, with core revenue growth in the first quarter driven by continued strength in PAs, said Maher Masoud, President and CEO of MaxCyte.
• We've added one new SPL thus far in 2025, TG Therapeutics in February, and continue to see a robust pipeline of SPL opportunities ahead of us.
• We remain operationally focused, making disciplined investments in high growth opportunities and process enhancements in the Company to drive long-term value.
• We are confident that our disciplined operational focus, highly differentiated offerings, and healthy financial foundation will continue to position MaxCyte for growth in 2025 and beyond.
• The integration of SeQure Dx is going smoothly, and we are very excited about the substantial opportunity from SeQure Dx's safety assessment services platforms over the long-term.

Industry Context

MaxCyte operates in the cell and gene therapy space, providing enabling platform technologies. The company's performance is influenced by the growth and challenges within this industry, including the increasing complexity of next-generation cell therapy programs and the need for efficient and scalable cell engineering solutions.

Comparison to Industry Standards

• MaxCyte's strategic platform licenses (SPLs) are similar to arrangements seen with companies like CRISPR Therapeutics and Vertex Pharmaceuticals, where technology platforms are licensed for therapeutic development.
• The company's focus on non-viral cell engineering aligns with the industry's need to address the limitations of viral vectors, as highlighted in the corporate presentation.
• MaxCyte's ExPERT platform competes with other cell engineering technologies, such as those offered by Lonza and Thermo Fisher Scientific, in terms of transfection efficiency, scalability, and regulatory compliance.
• The company's financial performance, including revenue growth and gross margins, can be compared to other life science companies in the cell and gene therapy tools and services sector.

Stakeholder Impact

• Shareholders may be concerned about the decrease in total revenue and the net loss, but reassured by the reiterated guidance and management's confidence.
• Employees may be affected by the company's focus on operational efficiency and disciplined investments.
• Customers will benefit from the continued development and improvement of MaxCyte's cell engineering platform.
• Suppliers may see continued demand for their products and services as MaxCyte expands its operations.

Next Steps

• MaxCyte will host a conference call on May 7, 2025, to discuss the financial results.
• The company will continue to focus on disciplined investments in high-growth opportunities and process enhancements.
• MaxCyte will continue to integrate SeQure Dx and explore opportunities for its safety assessment services.

Key Dates

Keywords

MaxCyte, financial results, core revenue, SPL Program, cell engineering, revenue guidance, Q1 2025